Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib ’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Study | Toxicology